AbbVie expands manufacturing presence in Ireland with a €60M investment

Ireland has become awash in manufacturing expansion projects, and AbbVie is the latest to get in on the action.

The government of Ireland announced that AbbVie is injecting €60 million ($58.9 million) into its manufacturing site in the town of Carrigtwohill, Ireland, a suburb of Cork City. According to AbbVie, the 14,000-square-foot facility has been operating since 2001 as a tablet and capsule production site for oncology and virology products. This latest expansion will have the site also support its aesthetics business.

Construction is set to start next year and be fully operational by 2025, employing an additional 70 people, but the exact size of the expansion was not initially given. Endpoints News reached out to AbbVie for further details on the expansion and will update the story accordingly.

The plant currently has 150 employees and has invested a total of €177 million ($173.8 million) into its operations since 2013.

Malcolm Garde

“This latest investment is a fantastic opportunity for the Cork site and a recognition of the expertise and commitment of our dedicated employees over the past 20 years. The expansion and associated cutting-edge technologies will help us to further develop our employees and attract new skilled talent,” said Malcom Garde, site director for AbbVie Cork in a statement.

AbbVie has a strong presence on the Emerald Isle, with seven other locations across the country in Dublin, Sligo and Mayo.

Ireland has become ripe for expansions throughout the year. Just a few days ago, J&J announced it was expanding its contact lens manufacturing site to the tune of over $100 million. Abbott Laboratories is also investing over $450 million in Kilkenny to build a new site to manufacture its glucose monitors.

Pharma companies such as J&J, Merck KGaA, Cambrex, Horizon, AstraZeneca and others have also all announced or kicked off major, multimillion-dollar expansion projects in Ireland.

manufacturing
pharma